Skip to main content
Canada’s most-awarded newsroom for a reason
Enjoy unlimited digital access
$1.99
per week
for 24 weeks
Canada’s most-awarded newsroom for a reason
$1.99
per week
for 24 weeks
Start Today
// //
Subscribe from $1.99/WK
Register
AdChoices

Biogen Inc NASDAQ: BIIB-Q

Today's Change
Volume
Real-Time Last Update Last Sale Cboe BZX Real-Time
Alerts Watchlist Portfolio

Today's Trading

Day Low 221.72
Day High 229.04
Open:227.69
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.

More stories below advertisement

Latest
investment ideas
Warren Buffett’s Berkshire pares drug holdings, sheds Axalta, Biogen
report on business
FDA wants probe into its approval of Alzheimer’s drug from Biogen
Subscriber content
u.s. business
Eli Lilly to seek accelerated U.S. FDA approval for its experimental Alzheimer’s drug this year
Subscriber content
stars and dogs
The Globe’s stars and dogs for the week
Subscriber content
inside the market
Market movers: Stocks that saw action on Tuesday - and why
Subscriber content
international business
U.S. FDA approves Biogen’s Alzheimer’s drug, sending its shares soaring
Subscriber content
Description
Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia, and a deep clinical pipeline ranging from Alzheimer's disease, lupus nephritis to neuropathic pain.

Fundamentals

Market Capitalization, $K
Shares Outstanding, K
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Zacks Investment Research, including Income Statements, Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

View Earnings zacks

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research.

Moderate Buy
View Estimates zacks

StockReports+

A premium report that provides detailed quantitative assessments of earnings, fundamentals, relative valuation, risk, price momentum and more. For subscribers only.

Download Premium PDF Refinitiv. Trademark. Data is Just the Beginning.

StockCalc

What is this stock worth in intrinsic value? View this premium StockCalc report to see this stock's valuation and how it was calculated using fundamental analysis. For subscribers only.

Download Premium PDF StockCalc

ValuEngine

A stock valuation and forecasting report include rating, fair value assessment, return forecasts, market ratio-based valuations and comparable analysis. Available for free with registration.

Download Free PDF ValueEngine logo

Latest Press Releases

More Stories
Sage Therapeutics and Biogen Announce Positive, One-Year Zuranolone 50 mg Data in the Ongoing Open-Label SHORELINE Study in Patients with MDD
Business Wire - Wed Dec 1, 5:30AM CST
Business Wire - PRTGAM
Wed Dec 1, 5:30AM CST
Sage Therapeutics, Inc. (Nasdaq: SAGE), and Biogen Inc. (Nasdaq: BIIB) today announced 12-month data for the cohort of patients (n=199), who received zuranolone 50 mg once nightly for 14-days as their initial dose in the ongoing Phase 3 open-label...
Visa, Target fall; TJX, Varex Imaging rise
Associated Press - Wed Nov 17, 3:18PM CST
Associated Press - AP
Wed Nov 17, 3:18PM CST
NEW YORK (AP) — Stocks that traded heavily or had substantial price changes Wednesday:
Update on Regulatory Review of Aducanumab in the European Union
Globe Newswire - Wed Nov 17, 6:30AM CST
Globe Newswire - PRTGAM
Wed Nov 17, 6:30AM CST
CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd. (Tokyo, Japan) announced today an update on the...
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 221.72 +0.99% increase
on 12/03/21
Period Open:279.59
Price movement based on the high, low and last over the given period.
284.59 -21.32% decrease
on 11/05/21
 -55.67 (-19.91%) decrease
since 11/03/21
3-Month 221.72 +0.99% increase
on 12/03/21
Period Open:333.60
Price movement based on the high, low and last over the given period.
332.87 -32.73% decrease
on 09/07/21
 -109.68 (-32.88%) decrease
since 09/03/21
52-Week 221.72 +0.99% increase
on 12/03/21
Period Open:244.09
Price movement based on the high, low and last over the given period.
468.55 -52.21% decrease
on 06/07/21
 -20.17 (-8.26%) decrease
since 12/03/20

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2021.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

© 2021 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies